In recognition of Cancer Research Month

As International Cancer Research Month draws to a close, I’ve been reflecting on how much progress has been made over the past 20 years and how it all translates into patient outcomes.

2017 was an exceptional year in Oncology drug development with approval of many new innovative therapies.  The pace of clinical development and the sheer volume of clinical data has been overwhelming.  There was a remarkable increase in the number of Phase III global trials being initiated, all in the hope of improving patient outcomes.  With ASCO fast approaching it will be exciting to see data from emerging treatments e.g. newer CAR T-cell therapies, immunotherapies, vaccines, precision therapies, new combinations of current therapies alongside new technologies for genomic profiling, biomarkers and personalised approaches to medicine in general.

I’m really proud to have worked in this industry alongside exceptionally dedicated and talented people who really want to make a difference.  Good luck to all my ex colleagues from Roche, Genentech and Acerta for a successful ASCO 2018! #cancerresearchmonth

Helen Bishop, MedEvent Partners